You are here: vision-research.eu » News » Newsdetails:

European Commission approves adalimumab for paediatric uveitis

The European Commission has approved adalimumab (Humira, AbbVie) as the first biologic treatment for chronic non-infectious anterior uveitis in paediatric patients from 2 years of age who have had an inadequate response to conventional therapy.